On August 19, 2025, AbbVie (NYSE: ABBV) formally closed the $2.1 billion purchase of Capstan Therapeutics. The agreement, which was first revealed on June 30, 2025, combines Capstan’s innovative targeted lipid nanoparticle (tLNP) platform technology with AbbVie’s well-established immunology expertise.
Breakthrough Technology Platform
Through the acquisition, AbbVie will have access to a potentially industry-first in vivo targeted lipid nanoparticle (tLNP) anti-CD19 CAR-T treatment candidate for autoimmune disorders mediated by B cells. AbbVie also gets access to Capstan’s exclusive tLNP platform, which is made to carry RNA payloads like mRNA that can be used to in vivo engineer particular cell types.
CPTX2309: Lead Asset
CPTX2309, Capstan’s flagship product, is presently undergoing Phase 1 studies to treat autoimmune disorders mediated by B cells. This novel treatment is a tLNP that produces CD19-specific, CD8+ CAR-T cells in vivo.
The treatment has several ground-breaking benefits:
- Achieves deep and quick B-cell reduction to produce long-lasting, medication-free remission.
- Removes the need for chemotherapy that depletes lymph.
- Avoids additional issues that come with traditional ex vivo CAR-T treatments.
With the acquisition now complete, we are excited to work together with the talented team at Capstan to advance our mission of transforming patient care,
The addition of CPTX2309 and Capstan’s tLNP platform strengthens our ability to deliver new treatments aimed at resetting the immune system and enables application of Capstan’s proprietary technology more broadly for in vivo programming of cells.
Jonathon Sedgwick
Strategic Impact
Through this acquisition, AbbVie will be able to take advantage of Capstan’s cutting-edge in vivo cell programming technology platform, which may expand applications beyond the original focus on autoimmune diseases. One important technological development that has the potential to revolutionize the development and delivery of cell treatments is the patented tLNP platform.
AbbVie’s dedication to revolutionizing patient care and creating cutting-edge therapies that try to rebuild the immune system in patients with difficult autoimmune diseases has reached a major turning point with the completion of this purchase.
Last Modified:
Graduated from the University of Kerala'20 with B.Sc. Botany & Biotechnology. Post-graduation in Biotechnology from the University of Kerala'22. Internship experience in Cancer Research.
